Stevens Capital Management LP Sells 2,873 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Stevens Capital Management LP reduced its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 76.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 890 shares of the medical equipment provider’s stock after selling 2,873 shares during the period. Stevens Capital Management LP’s holdings in Intuitive Surgical were worth $300,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Portside Wealth Group LLC grew its position in Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in Intuitive Surgical by 58.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after purchasing an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC bought a new stake in Intuitive Surgical in the fourth quarter worth $230,000. Blair William & Co. IL raised its stake in shares of Intuitive Surgical by 3.1% during the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after acquiring an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Intuitive Surgical by 21.2% during the third quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after acquiring an additional 129,194 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intuitive Surgical

In related news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. Insiders sold a total of 249,418 shares of company stock worth $96,300,959 in the last three months. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded up $2.21 during trading hours on Friday, hitting $375.33. 927,473 shares of the company were exchanged, compared to its average volume of 1,658,417. The company’s 50 day moving average price is $386.26 and its 200-day moving average price is $345.39. The stock has a market capitalization of $133.13 billion, a price-to-earnings ratio of 67.75, a PEG ratio of 4.84 and a beta of 1.36. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 EPS. On average, equities analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ISRG. Barclays upped their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Piper Sandler upped their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Robert W. Baird decreased their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research report on Friday, April 19th. Finally, Raymond James raised their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.